Geon-Ho Jahng1,2, Ji Yoon Lee3, Hak Young Rhee4, Wonchae Choe5, and Chang-Woo Ryu1,2
1Radiology, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, 2Medicine, Kyung Hee University, Seoul, Korea, Republic of, 3Biomedical Engineering, Kyung Hee University, Yongin-si, Korea, Republic of, 4Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, 5Biochemistry and Molecular Biology, Kyung Hee University, Seoul, Korea, Republic of
1Radiology, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, 2Medicine, Kyung Hee University, Seoul, Korea, Republic of, 3Biomedical Engineering, Kyung Hee University, Yongin-si, Korea, Republic of, 4Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, 5Biochemistry and Molecular Biology, Kyung Hee University, Seoul, Korea, Republic of
Considering the potential roles of each enzyme in pathogenesis
of AD, the plasma circulating levels of these enzymes possibly reflect the
pathological changes of the brain in AD and would be candidates for blood-based
biomarkers.
Table
1. Summary of the demographic data, results of the neuropsychological
test, the three blood-based biomarkers, and results of statistical analyses.
Figure 1. Results of the voxel-based multiple regression analyses between brain tissue volumes and the levels of the three blood biomarkers
GMV, gray matter volume; WMV, white matter volume; PPIA, peptidylprolyl isomerase A (PPIA, known as cyclophilin A, CyPA); HO-1, heme oxygenase-1; IRE1, and inositol-requiring enzyme 1
